Humasis Co

Humasis Co PP&E per Employee

The PP&E per Employee of Humasis Co (205470.KQ) as of Nov 11, 2026 is 289.36 M KRW. In the previous year, PP&E per Employee was 239.09 M KRW — a change of 21.03% (higher).

PP&E per Employee

289.36 MKRW

YoY

21.03%

Last updated:

PP&E per Employee of Humasis Co is 2024 289.36 M KRW. PP&E per Employee of Humasis Co was 2023 239.09 M KRW. It decreases by 21.03% higher compared to the previous year.

The Humasis Co PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2017
31.51 M KRW
Jan 1, 2018
33.29 M KRW
Jan 1, 2019
43.25 M KRW
Jan 1, 2020
102.32 M KRW
Jan 1, 2021
182.85 M KRW
Jan 1, 2022
327.31 M KRW
Jan 1, 2023
239.09 M KRW
Jan 1, 2024
289.36 M KRW
The Humasis Co PP&E per Employee history
YEARPP&E per EmployeeYoY
289.36 MKRW+21.03%
239.09 MKRW-26.95%
327.31 MKRW+79.01%
182.85 MKRW+78.70%
102.32 MKRW+136.56%
43.25 MKRW+29.94%
33.29 MKRW+5.63%
31.51 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

PP&E per Employee of Humasis Co is 289.36 M KRW in 2024.

PP&E per Employee of Humasis Co changed from 239.09 M KRW to 289.36 M KRW, representing a 21.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Humasis Co since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Humasis Co

All Key Metrics — Humasis Co